If you are a current Jazz employee please apply via the Internal Career site.

Jazz Pharmaceuticals is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.

The Director, Global Value and HEOR is a high-visibility, dual-mandate strategic leadership and hands-on execution role within the Evidence and Value Generation department. This role is directly accountable for defining and executing the global and US payer evidence strategies in Oncology.

The Director will lead the global HEOR activities and strategies in gastroesophageal adenocarcinoma (GEA), preparing the asset for major commercial and reimbursement milestones worldwide. Simultaneously, the Director acts as the lead HEOR partner for a major Oncology asset’s expanding clinical pipeline, proactively embedding payer and Health Technology Assessment (HTA) requirements into ongoing and future Phase 2 and Phase 3 development programs (including earlier lines of therapy, novel combination regimens, and broader HER2-expressing solid tumors).

Operating across both global strategy and direct US operational HEOR delivery, the Director serves as the strategic evidence engine that substantiates the value story developed by the Market Access team. The Director is a key stakeholder in both the value narrative and the IEGP—holding direct responsibility for the payer evidence strategy that validates this narrative through rigorous, peer-reviewed, and commercially compelling evidence assets.

The Director works in seamless partnership with the dedicated EU/INT HEOR team to co-create European and international HTA evidence packages (including EU Joint Clinical Assessment [JCA] readiness), while directly serving as the US HEOR lead in driving US access deliverables (AMCP dossiers, US formulary budget impact models, and Payer Field Team enablement).

The post holder not only needs to be an excellent strategist, but also be a deep expert delivering projects with vendors, and sometimes doing models etc in house rather than outsourcing them. An ability to create a virtuous circle whereby they use their depth of knowledge to inform strategy, and their knowledge of strategy to inform the evidence that we generate is key to long term success.

Essential Functions/Responsibilities

1. US HEOR Leadership & Payer Field Enablement (Dual Mandate)

Dedicated US HEOR Accountability: Serve as the designated HEOR lead for the US market, translating US access and reimbursement priorities into robust evidence strategies that support commercial, Medicare (Part B and Part D), and Medicaid access.

US Core Deliverables: Lead the direct execution, authoring, and annual updating of US-specific evidence assets, including AMCP dossiers, US commercial/Medicare budget impact models, and state Medicaid submission packages.

Payer Field Team Collaboration & Enablement: Partner closely with US Payer Field Team to translate complex HEOR data into customer-facing, interactive economic models, slide decks, and digital tools. Ensure all field materials strictly comply with FDAMA Section 114, 21st Century Cures Act, and FDA guidance on communications with population health decision-makers.

US Policy, Legislative, & ICER Preparedness: Monitor and integrate the impact of evolving US health policy into evidence generation plans (e.g., Inflation Reduction Act [IRA], CMS Drug Price Negotiation, Part D redesign). Formulate strategic evidence roadmaps and response readiness for US value assessments (e.g., ICER reviews, NCCN Evidence Blocks).

Innovative Contracting & Value-Based Agreements: Collaborate with US Market Access to evaluate the feasibility of innovative payment models, providing methodological guidance on measurable clinical and economic endpoints for value-based contracts and risk-sharing arrangements.

2. Phase 2/3 Clinical Trial & Early Evidence Integration

Early Payer & Access Evidence Integration: Partner proactively with Clinical Development Leads, Biostatistics, and Clinical Operations to embed payer-, HTA-, and reimbursement-critical evidentiary requirements directly into Phase 2 and Phase 3 clinical trial protocols.

Trial Protocol Optimization: Advocate for value-enhancing trial protocol features, including clinically meaningful active comparators, optimized inclusion/exclusion criteria, relevant lines of therapy, and payer-recognized clinical and functional endpoints.

Patient-Centered Outcomes & Label Claims: Collaborate with Patient-Centered Outcomes (PCO) and Clinical teams to integrate validated Patient-Reported Outcomes (PROs), health-related quality of life (HRQoL), and healthcare resource utilization (HCRU) measures into pivotal clinical trials, supporting both reimbursement and potential regulatory label claims.

Rare Disease Clinical Evidence Strategy: For rare disease programs, proactively design strategies to navigate small sample sizes, heterogeneous clinical presentations, single-arm studies, and surrogate endpoints by embedding natural history data, disease progression markers, and patient registry benchmarks into trial planning.

3. Advanced Health Economic Modeling Strategy & Execution

Innovative Modeling Strategy: Formulate and execute innovative, fit-for-purpose health economic modeling strategies across the product lifecycle (including early conceptual economic models, cost-effectiveness analyses [CEA], cost-utility analyses [CUA], and budget impact models [BIM]).

Navigating High Uncertainty & Rare Disease Paradigms: Apply creative modeling solutions to address data gaps, small patient cohorts, immature survival data, and clinical trial uncertainty typical of rare diseases and targeted therapies (e.g., dynamic disease modeling, Bayesian extrapolation, structured expert elicitation, and advanced scenario testing).

Global Core Model Architecture: Direct the technical design, development, and validation of transparent, adaptable global core economic models that can be seamlessly leveraged by the EU/INT HEOR team for national HTA submissions and by the US team for commercial and public payers.

4. Payer Evidence Strategy & Delivery of Core Assets

Substantiating the Value Story: Formulate and execute the end-to-end payer evidence generation strategy required to substantiate, validate, and communicate the product value narrative developed by the Market Access team.

Global Core Deliverables: Lead the direct execution, authoring, and updating of foundational global evidence assets, including Global Value Dossiers (GVDs), systematic literature reviews (SLRs), and global evidence libraries.

Collaborative HTA Evidence Support: Partner with the dedicated EU/INT HEOR team to define HTA strategy and co-deliver the clinical and economic evidence foundations (e.g., indirect treatment comparisons [ITCs], network meta-analyses [NMAs], and economic model adaptations) required for European and International HTA bodies (such as EU JCA, NICE, SMC, G-BA, HAS, CADTH).

Real-World Evidence (RWE) & Natural History: Collaborate with RWE, epidemiology, and data analytics colleagues to design and deliver natural history studies, burden-of-illness evaluations, treatment patterns, and comparative effectiveness analyses using claims (e.g., MarketScan, Optum, Medicare 100% SAF), electronic health records (EHR), and disease registries.

5. Launch Readiness, Lifecycle Management (LCM) & Label Expansions

Global & US Launch Preparation: Lead the HEOR workstream for launch readiness governance; ensure timely completion of core access deliverables (GVDs, AMCP dossiers, ITCs, budget impact models, economic evaluations) aligned with global regulatory submission milestones and launch roadmaps.

Lifecycle Management (LCM) Evidence Strategy: Formulate and execute proactive evidence strategies to maximize the long-term value of inline assets, identifying strategic evidence requirements across supplemental indications, line extensions, new formulations, and patient subpopulations.

Support for Label Expansions: Partner with Clinical Development, Regulatory Affairs, and Commercial/Access teams to design evidence generation plans supporting sBLA/sNDA submissions and subsequent rapid payer uptake in expanded target populations.

Value Defense & Post-Launch Evidence Optimization: Collaborate on the design pf post-marketing evidence programs (including phase 4 studies, post-authorization commitments, and long-term registry follow-up) to substantiate clinical differentiation, defend value against standard-of-care evolution or competitor entries, and support reimbursement re-assessments or price renegotiations.

6. Cross-Functional Partnership, Governance & Mentorship

IEGP Stakeholder & Evidence Delivery: Serve as the core GVHEOR stakeholder in Integrated Evidence Generation Plan (IEGP) governance, ensuring that all HEOR and payer evidentiary commitments within the plan are clearly scoped, resourced, and delivered on time across pipeline and inline assets.

Commercial & Access Matrix Alignment: Act as the primary strategic evidence partner to Market Access, Brand Teams, and Medical Affairs, ensuring evidence plans continuously anticipate evolving payer requirements and reinforce value demonstration.

Regional HEOR Alignment: Maintain an agile, collaborative operating model with the EU/INT HEOR team, balancing global scalability with national submission requirements.

Scientific Dissemination & Publication: Lead the HEOR publication strategy; author high-impact manuscripts in peer-reviewed journals and present findings at major scientific, clinical, and health economic congresses (e.g., ISPOR, AMCP, ICER, disease-specific forums).

Talent Mentorship & Matrix Leadership: Mentor junior scientists, cross-functional colleagues, and HEOR fellows; champion methodological excellence and raise internal organizational understanding of HEOR impact.

Compliance & Governance: Ensure all evidence generation activities, advisory boards, field communication tools, and scientific collaborations strictly comply with legal, regulatory, and corporate standards.

Required Knowledge, Skills, and Abilities

Dual Global & US HEOR Acumen: Deep working knowledge of US managed care archetypes (commercial health plans, PBMs, Medicare Part B/D, Medicaid) alongside major international HTA systems (EU JCA, NICE, G-BA, CADTH). Thorough familiarity with US compliance standards governing payer communications (FDAMA Section 114 / 21st Century Cures Act).

Health Economic Modeling Mastery: Advanced technical and conceptual expertise in health economic modeling (Markov state-transition models, partitioned survival models, microsimulation, discrete event simulation). Proven ability to formulate creative modeling frameworks when working with data uncertainty, small patient cohorts, or novel clinical trial endpoints.

Payer Field Collaboration & Tool Development: Demonstrated track record of partnering with US Payer Field Teams (Medical Value Liaisons, Outcomes Liaisons) to develop interactive, customer-facing economic models and value presentation tools.

Rare Disease / Orphan Drug Access Expertise: Practical understanding of the unique evidence generation challenges in rare diseases, including small patient sample sizes, registry utilization, natural history studies, external control arms, and specialized orphan drug HTA assessment mechanisms (e.g., NICE Highly Specialised Technologies [HST] pathways).

Launch Readiness & Lifecycle Management: Proven track record in leading HEOR workstreams for global and US launch preparation, cross-functional launch governance, and designing evidence generation plans supporting inline lifecycle management, label expansions, and value defense.

Clinical Trial Interface & Protocol Optimization: Demonstrated experience collaborating with Clinical Development and Biostatistics teams to influence Phase 2/3 study designs, comparator selection, and the integration of HEOR/PRO endpoints.

Policy & Value Framework Literacy: Strong strategic understanding of US health policy developments (e.g., Inflation Reduction Act [IRA], CMS price negotiations) and experience preparing for or responding to value assessment bodies (e.g., ICER).

Dual Strategic & Execution Capability: Proven ability to balance setting overarching global and US evidence strategies with rolling up sleeves to directly execute and author complex deliverables (AMCP dossiers, GVDs, NMAs, economic models, and RWE protocols).

Matrix Leadership & Mentorship: Exceptional ability to lead, influence, and collaborate cross-functionally across Clinical Development, Medical Affairs, Market Access, Regulatory, and Commercial without formal authority; demonstrated ability to mentor junior researchers.

Project, Budget, and Vendor Management: Proven experience managing multi-million-dollar research budgets, conducting rigorous vendor selection, and directing external CROs and academic partners to deliver on time and on budget.

Required/Preferred Education and Licenses

Required Education: A Master’s degree (MSc, MS, MPH, PhD) in Health Economics, Outcomes Research, , Pharmacoeconomics, or a closely related quantitative field.

Experience:

Minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm.

Experience with oncology assets preferred.

Demonstrated track record of leading HEOR strategy and executing evidence deliverables for marketed, inline pharmaceutical products (including lifecycle management, label expansions, and value defense).

Deep understanding of US payer and population health decision makers including Oncology Pathways

Experience managing regional trade offs on evidence needs as part of Phase2/3 protocol development.

Launch lead for at least 2 assets as US HEOR lead, or country level HTA lead

Preferred above country HEOR product leadership

Proven track record serving as the US HEOR lead or driving US pre-launch HEOR deliverables (e.g., AMCP PIE dossiers, US budget impact models, payer field enablement), or significant exposure to these deliverables from a global role..

Experience conducting post-marketing RWE, patient registry studies, and economic evaluations in rare diseases, specialized medicine, or complex chronic conditions.

Substantial experience collaborating with regional HEOR teams (e.g., EU/INT) to deliver evidence packages supporting global HTA re-assessments, renewals, or pricing renegotiations.

Strong peer-reviewed publication record in health economics and outcomes research.

#LI-DM1

#LI-Remote

Jazz Pharmaceuticals is an equal opportunity/affirmative action employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any characteristic protected by law.

FOR US BASED CANDIDATES ONLY

Jazz Pharmaceuticals, Inc. is committed to fair and equitable compensation practices and we strive to provide employees with total compensation packages that are market competitive. For this role, the full and complete base pay range is: $212,000.00 - $318,000.00

Individual compensation paid within this range will depend on many factors, including qualifications, skills, relevant experience, job knowledge, and other pertinent factors. The goal is to ensure fair and competitive compensation aligned with the candidate's expertise and contributions, within the established pay framework and our Total Compensation philosophy. Internal equity considerations will also influence individual base pay decisions. This range will be reviewed on a regular basis.

At Jazz, your base pay is only one part of your total compensation package. The successful candidate may also be eligible for a discretionary annual cash bonus or incentive compensation (depending on the role), in accordance with the terms of the Company's Global Cash Bonus Plan or Incentive Compensation Plan, as well as discretionary equity grants in accordance with Jazz's Long Term Equity Incentive Plan.

The successful candidate will also be eligible to participate in various benefits offerings, including, but not limited to, medical, dental and vision insurance, 401k retirement savings plan, and flexible paid vacation. For more information on our Benefits offerings please click here: https://careers.jazzpharma.com/benefits.html.

Director, Global Value and Health Economics and Outcomes Research